|
Drugmakers and antibiotics 制药商和抗生素 The path of least resistance 最省事的办法 Governments reckon that drug firms researchefforts need a shot in the arm 政府认为需要鼓励药企的研发工作 A GROWING worry in medicine is bugs increasingresistance to antibiotics. 随着细菌对抗生素的抵抗性越来越强，人们对药物效用的担忧与日俱增。 At AstraZeneca s research centre near Boston, scientists toil to find new weapons. 在波士顿附近的阿斯利康研究中心里，科学家们费力地寻找着对付细菌的新武器。 Machines screen thousands of drugs each year, robotic arms nimbly handling plates ofcompounds to test their effect on bacteria. 研究所里每年仪器筛查成千上万的药物，用灵活的机械手测试众多药物成分对细菌的作用。 But progress is slow. 可是进程却很缓慢。 It is not our hottest area in terms of commercial return, admits Martin Mackay,AstraZeneca s research and development chief. 阿斯利康研究和发展组组长马丁麦基承认道：从商业收益来看，研制抗生素并不是最赚钱的。 | 
